Product Name :
ACT 178882
Description:
ACT 178882 is a new Renin inhibitor with an IC50 of 1.4 nM.
CAS:
1007392-69-9
Molecular Weight:
647.03
Formula:
C33H38Cl3N3O4
Chemical Name:
(3R,4S)-N-{[2-chloro-5-(2-methoxyethyl)phenyl]methyl}-N-cyclopropyl-4-{6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl}piperidine-3-carboxamide
Smiles :
CC1C=C(Cl)C(OCCOC2=CC=C(C=N2)[C@H]2CCNC[C@@H]2C(=O)N(CC2=CC(CCOC)=CC=C2Cl)C2CC2)=C(Cl)C=1
InChiKey:
PGSRKJVMAOWDEC-SXOMAYOGSA-N
InChi :
InChI=1S/C33H38Cl3N3O4/c1-21-15-29(35)32(30(36)16-21)43-14-13-42-31-8-4-23(18-38-31)26-9-11-37-19-27(26)33(40)39(25-5-6-25)20-24-17-22(10-12-41-2)3-7-28(24)34/h3-4,7-8,15-18,25-27,37H,5-6,9-14,19-20H2,1-2H3/t26-,27+/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Ceftobiprole} MedChemExpress|{Ceftobiprole} Antibiotic|{Ceftobiprole} Purity & Documentation|{Ceftobiprole} References|{Ceftobiprole} manufacturer|{Ceftobiprole} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Pramipexole} web|{Pramipexole} Neuronal Signaling|{Pramipexole} Protocol|{Pramipexole} Data Sheet|{Pramipexole} manufacturer|{Pramipexole} Cancer}
Additional information:
ACT 178882 is a new Renin inhibitor with an IC50 of 1.PMID:34337881 4 nM.|Product information|CAS Number: 1007392-69-9|Molecular Weight: 647.03|Formula: C33H38Cl3N3O4|Chemical Name: (3R,4S)-N-{[2-chloro-5-(2-methoxyethyl)phenyl]methyl}-N-cyclopropyl-4-{6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl}piperidine-3-carboxamide|Smiles: CC1C=C(Cl)C(OCCOC2=CC=C(C=N2)[C@H]2CCNC[C@@H]2C(=O)N(CC2=CC(CCOC)=CC=C2Cl)C2CC2)=C(Cl)C=1|InChiKey: PGSRKJVMAOWDEC-SXOMAYOGSA-N|InChi: InChI=1S/C33H38Cl3N3O4/c1-21-15-29(35)32(30(36)16-21)43-14-13-42-31-8-4-23(18-38-31)26-9-11-37-19-27(26)33(40)39(25-5-6-25)20-24-17-22(10-12-41-2)3-7-28(24)34/h3-4,7-8,15-18,25-27,37H,5-6,9-14,19-20H2,1-2H3/t26-,27+/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|The median time to Cmax (tmax) for ACT 178882 is prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) is unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively. Using treatment A as reference, the geometric mean ratio (90% CI) is 1.62 (1.36 to 1.94) for Cmax and 2.02 (1.75 to 2.34) for AUC∞, indicating a significant interaction between ACT 178882 and diltiazem.|Products are for research use only. Not for human use.|
